153 related articles for article (PubMed ID: 34967844)
21. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
22. Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer.
Sukumar JS; Quiroga D; Kassem M; Grimm M; Shinde NV; Appiah L; Palettas M; Stephens J; Gatti-Mays ME; Pariser A; Cherian M; Stover DG; Williams N; Van Deusen J; Wesolowski R; Lustberg M; Ramaswamy B; Sardesai S
Breast Cancer Res Treat; 2021 Nov; 190(2):183-188. PubMed ID: 34498153
[TBL] [Abstract][Full Text] [Related]
23. The risk of menopausal symptoms in premenopausal breast cancer patients and current pharmacological prevention strategies.
Lei YY; Yeo W
Expert Opin Drug Saf; 2021 Oct; 20(10):1163-1175. PubMed ID: 33951990
[No Abstract] [Full Text] [Related]
24. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men: Results from the MALE Phase 2 Randomized Clinical Trial.
Reinisch M; Seiler S; Hauzenberger T; Kamischke A; Schmatloch S; Strittmatter HJ; Zahm DM; Thode C; Furlanetto J; Strik D; Möbus V; Reimer T; Sinn BV; Stickeler E; Marmé F; Janni W; Schmidt M; Rudlowski C; Untch M; Nekljudova V; Loibl S
JAMA Oncol; 2021 Apr; 7(4):565-572. PubMed ID: 33538790
[TBL] [Abstract][Full Text] [Related]
26. [Anti-Müllerian hormone as a new marker of the ovarian reserve function preservation by goserelin during (neo)adjuvant chemotherapy for young breast cancer patients].
Wang SY; Wang S
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 51(3):536-541. PubMed ID: 31209428
[TBL] [Abstract][Full Text] [Related]
27. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.
Gerber B; von Minckwitz G; Stehle H; Reimer T; Felberbaum R; Maass N; Fischer D; Sommer HL; Conrad B; Ortmann O; Fehm T; Rezai M; Mehta K; Loibl S;
J Clin Oncol; 2011 Jun; 29(17):2334-41. PubMed ID: 21537042
[TBL] [Abstract][Full Text] [Related]
28. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial.
Leonard RCF; Adamson DJA; Bertelli G; Mansi J; Yellowlees A; Dunlop J; Thomas GA; Coleman RE; Anderson RA;
Ann Oncol; 2017 Aug; 28(8):1811-1816. PubMed ID: 28472240
[TBL] [Abstract][Full Text] [Related]
29. No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial.
Demeestere I; Brice P; Peccatori FA; Kentos A; Dupuis J; Zachee P; Casasnovas O; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
J Clin Oncol; 2016 Aug; 34(22):2568-74. PubMed ID: 27217453
[TBL] [Abstract][Full Text] [Related]
30. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials.
Del Mastro L; Ceppi M; Poggio F; Bighin C; Peccatori F; Demeestere I; Levaggi A; Giraudi S; Lambertini M; D'Alonzo A; Canavese G; Pronzato P; Bruzzi P
Cancer Treat Rev; 2014 Jun; 40(5):675-83. PubMed ID: 24360817
[TBL] [Abstract][Full Text] [Related]
31. Gonadotropin-Releasing Hormone Analogs for Gonadal Protection During Gonadotoxic Chemotherapy: A Systematic Review and Meta-Analysis.
Sofiyeva N; Siepmann T; Barlinn K; Seli E; Ata B
Reprod Sci; 2019 Jul; 26(7):939-953. PubMed ID: 30270741
[TBL] [Abstract][Full Text] [Related]
32. Gonadotropin-Releasing Hormone Agonists during Gonadal Chemotherapy for the Effect on Pregnancy Outcome and Ovarian Function in Premenopausal Patients with Breast Cancer: A Systematic Review and Meta-Analysis.
Yuan Y; Zhang C; Lei X; Ren T; Chen H; Zhao Q
Breast Care (Basel); 2023 Aug; 18(4):270-278. PubMed ID: 37900550
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.
Furlanetto J; Marmé F; Seiler S; Thode C; Untch M; Schmatloch S; Schneeweiss A; Bassy M; Fasching PA; Strik D; Stickeler E; Schem C; Karn T; Grischke EM; Denkert C; van Mackelenbergh M; Müller V; Nekljudova V; Loibl S
Eur J Cancer; 2021 Jul; 152():193-203. PubMed ID: 34116270
[TBL] [Abstract][Full Text] [Related]
34. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
Munster PN; Moore AP; Ismail-Khan R; Cox CE; Lacevic M; Gross-King M; Xu P; Carter WB; Minton SE
J Clin Oncol; 2012 Feb; 30(5):533-8. PubMed ID: 22231041
[TBL] [Abstract][Full Text] [Related]
35. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis.
Clowse ME; Behera MA; Anders CK; Copland S; Coffman CJ; Leppert PC; Bastian LA
J Womens Health (Larchmt); 2009 Mar; 18(3):311-9. PubMed ID: 19281314
[TBL] [Abstract][Full Text] [Related]
36. Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and meta-analysis.
Silva C; Caramelo O; Almeida-Santos T; Ribeiro Rama AC
Hum Reprod; 2016 Dec; 31(12):2737-2749. PubMed ID: 27664208
[TBL] [Abstract][Full Text] [Related]
37. The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress.
Kim HA; Ahn SH; Nam SJ; Park S; Ro J; Im SA; Jung YS; Yoon JH; Hur MH; Choi YJ; Lee SJ; Jeong J; Cho SH; Kim SY; Lee MH; Kim LS; Moon BI; Kim TH; Park C; Kim SJ; Jung SH; Park H; Gwak GH; Kang SH; Kim JG; Kim J; Choi SY; Lim CW; Kim D; Yoo Y; Song YJ; Kang YJ; Jung SS; Shin HJ; Lee KJ; Han SH; Lee ES; Han W; Kim HJ; Noh WC
BMC Cancer; 2016 May; 16():319. PubMed ID: 27197523
[TBL] [Abstract][Full Text] [Related]
38. Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors.
Suh KJ; Kim SH; Lee KH; Kim TY; Kim YJ; Han SW; Kang E; Kim EK; Kim K; No JH; Han W; Noh DY; Lee M; Kim HS; Im SA; Kim JH
Cancer Res Treat; 2017 Oct; 49(4):1153-1163. PubMed ID: 28253566
[TBL] [Abstract][Full Text] [Related]
39. GnRHa for Ovarian Protection and the Association between AMH and Ovarian Function during Adjuvant Chemotherapy for Breast Cancer.
Zhong Y; Lin Y; Cheng X; Huang X; Zhou Y; Mao F; Wang Y; Guan J; Shen S; Xu Y; Peng L; Li Y; Cao X; Sun Q
J Cancer; 2019; 10(18):4278-4285. PubMed ID: 31413747
[No Abstract] [Full Text] [Related]
40. Gonadotropin-releasing hormone agonist protects ovarian function in young patients with ovarian malignancy undergoing platinum-based chemotherapy: A prospective study.
Xie Y; Duan H; Wang D; Li H; Jia J; Zhang J; Li L
Front Oncol; 2022; 12():986208. PubMed ID: 36338740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
